Compare AKTX & PRSO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AKTX | PRSO |
|---|---|---|
| Founded | N/A | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Semiconductors |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.1M | 8.5M |
| IPO Year | N/A | 2001 |
| Metric | AKTX | PRSO |
|---|---|---|
| Price | $0.23 | $0.82 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 1 |
| Target Price | $2.53 | ★ $3.00 |
| AVG Volume (30 Days) | 363.5K | ★ 521.6K |
| Earning Date | 11-13-2025 | 03-18-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $13,001,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $35.76 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 2.15 |
| 52 Week Low | $0.22 | $0.52 |
| 52 Week High | $1.73 | $2.37 |
| Indicator | AKTX | PRSO |
|---|---|---|
| Relative Strength Index (RSI) | 32.15 | 37.06 |
| Support Level | $0.22 | $0.91 |
| Resistance Level | $0.25 | $0.92 |
| Average True Range (ATR) | 0.02 | 0.09 |
| MACD | 0.00 | -0.02 |
| Stochastic Oscillator | 12.55 | 2.15 |
Akari Therapeutics PLC is an oncology company developing next-generation antibody-drug conjugates (ADCs) designed around novel, proprietary cancer-killing toxins (payloads). The company believes these novel payloads may have the potential to transform the efficacy and safety outcomes of ADCs as cancer therapies beyond options that are currently available or in development. Its lead product candidate is AKTX-101, a preclinical stage Trop2-targeting ADC that combines PH1 with the Trop2 antibody, which is expressed in the highest number of solid tumor cancer types, including lung, breast, colon and prostate.
Peraso Inc is a fabless semiconductor company focused on the development and sale of: i) millimeter wavelength wireless technology, or mmWave, semiconductor devices and antenna modules based on its proprietary semiconductor devices and ii) performance of non-recurring engineering, or NRE, services and licensing of intellectual property, or IP. The company's primary focus is the development of mmWave, which is generally described as the frequency band from 24 Gigahertz, or GHz, to 300 GHz. Geographically the company generates revenue from the United States, Hong Kong, Taiwan, and the Rest of the World.